Compare · NVO vs THRD
NVO vs THRD
Side-by-side comparison of Novo Nordisk A/S (NVO) and Third Harmonic Bio Inc. (THRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and THRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $183.82B.
- Over the past year, NVO is down 34.2% and THRD is up 4.5% - THRD leads by 38.7 points.
- NVO has hit the wire 5 times in the past 4 weeks while THRD has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for THRD).
- Company
- Novo Nordisk A/S
- Third Harmonic Bio Inc.
- Price
- $41.18+6.93%
- $5.38-0.09%
- Market cap
- $183.82B
- -
- 1M return
- +13.32%
- -0.92%
- 1Y return
- -34.24%
- +4.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest THRD
- CEO Holles Natalie C. disposed of 1,218,836 shares, closing all direct ownership in the company (SEC Form 4)
- Director Seidel Hans Martin disposed of 85,753 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Soloway Thomas P
- Director Iwicki Mark T disposed of 128,631 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Chief Financial & Bus. Officer Murphy Christopher M.
- SEC Form 4 filed by Director Gladstone Michael
- Director Bonita David P disposed of 5,779,071 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by Third Harmonic Bio Inc.
- SEC Form EFFECT filed by Third Harmonic Bio Inc.
- SEC Form 8-K filed by Third Harmonic Bio Inc.